Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peripheral naïve CD8+ T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a biomarker study.
Huang C, Xu B, Zhu XD, Shen YH, Li ML, Zhu JJ, Zhou J, Fan J, Sun HC. Huang C, et al. Among authors: zhu jj, zhu xd. Cancer Commun (Lond). 2022 Nov;42(11):1226-1230. doi: 10.1002/cac2.12350. Epub 2022 Aug 22. Cancer Commun (Lond). 2022. PMID: 35994567 Free PMC article. No abstract available.
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Zhu XD, Huang C, Shen YH, Xu B, Ge NL, Ji Y, Qu XD, Chen L, Chen Y, Li ML, Zhu JJ, Tang ZY, Zhou J, Fan J, Sun HC. Zhu XD, et al. Among authors: zhu jj. Ann Surg Oncol. 2023 May;30(5):2782-2790. doi: 10.1245/s10434-022-12530-z. Epub 2022 Sep 30. Ann Surg Oncol. 2023. PMID: 36178565 Free PMC article.
Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
Xu B, Zhu XD, Shen YH, Zhu JJ, Liu J, Li ML, Tang PW, Zhou J, Fan J, Sun HC, Huang C. Xu B, et al. Among authors: zhu jj, zhu xd. Front Immunol. 2022 Nov 25;13:1016736. doi: 10.3389/fimmu.2022.1016736. eCollection 2022. Front Immunol. 2022. PMID: 36505445 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36869918
Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers.
Wu M, Hau PM, Li L, Tsang CM, Yang Y, Taghbalout A, Chung GT, Hui SY, Tang WC, Jillette N, Zhu JJ, Lee HHY, Kong EL, Chan MSA, Chan JYK, Ma BBY, Chen MR, Lee C, To KF, Cheng AW, Lo KW. Wu M, et al. Among authors: zhu jj. Nat Commun. 2024 May 3;15(1):3729. doi: 10.1038/s41467-024-48031-8. Nat Commun. 2024. PMID: 38702330 Free PMC article.
1,226 results